Navigation Links
Chimerix Files Registration Statement for Proposed Initial Public Offering
Date:3/8/2013

RESEARCH TRIANGLE PARK, N.C., March 8, 2013 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock.  The number of shares to be offered and the price range for the offering have not been determined.

Morgan Stanley and Cowen and Company are acting as joint book-running managers for the offering.  William Blair and Lazard Capital Markets are acting as co-managers.

The offering will be made only by means of a prospectus.  When available, copies of the preliminary prospectus relating to the offering may be obtained from: Morgan Stanley & Co., LLC, Attn: Prospectus Department, 180 Varick Street, New York, New York 10014, or by calling toll free 1-866-718-1649 or emailing at prospectus@morganstanley.com; or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by calling (631) 274-2806, or faxing (631) 254-7140.

A registration statement relating to these securities has been filed with the SEC, but has not yet become effective.  These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Chimerix and CMX001
Chimerix is committed to the discovery, development and commercialization of novel, oral antiviral therapeutics designed to transform patient care in areas of high unmet medical need. The Company's proprietary lipid technology has given rise to two clinical-stage lipid acyclic nucleoside phosphonates, CMX001 and CMX157, which have demonstrated the potential for enhanced activity and safety in convenient, orally administered dosing regimens. 

Chimerix's lead product candidate, CMX001, is a broad spectrum, oral nucleotide analog lipid-conjugate that blocks replication of double-stranded DNA (dsDNA) viruses, including cytomegalovirus (CMV), adenovirus (AdV), BK virus and herpes simplex virus.  CMX001 has completed Phase 2 clinical development for the prevention of CMV in hematopoietic stem cell transplant (HSCT) recipients.  Chimerix is also conducting a Phase 2 study in HSCT recipients which is evaluating CMX001 as a preemptive therapy for AdV disease, an often-fatal infection which has no approved therapies.  Since 2009, Chimerix has made CMX001 available under expanded access regulations to over 80 transplant centers worldwide for the treatment of over 430 patients with life-threatening dsDNA viral infections.  Chimerix anticipates initiating SUPPRESS, its Phase 3 study of CMX001 for the prevention of CMV infection in adults undergoing HSCT, in 2013.   

Chimerix is also developing CMX001 as a potential medical countermeasure against smallpox under a contract from the Biomedical Advanced Research and Development Authority (BARDA). 

Chimerix's second product candidate, CMX157, an oral nucleotide analog lipid-conjugate in Phase 1 development for the treatment of HIV infection, was licensed to Merck in July 2012.   


'/>"/>
SOURCE Chimerix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Demonstrating the Safety and Efficacy of Chimerixs Antiviral CMX001 Presented at BMT Tandem Meetings
2. Data Related to Chimerixs Antiviral CMX001 to be Presented in Three Poster Sessions at the BMT Tandem Meetings
3. Chimerix Presents Data Highlighting Burden Of Care Associated With Current Antiviral Therapies In Stem Cell Transplantation
4. Chimerix Signs Worldwide License Agreement With Merck For CMX157, A Novel Candidate For The Treatment Of HIV
5. Chimerixs Broad Spectrum Antiviral Therapeutic, CMX001, Demonstrates Potential To Mitigate BK Virus Associated End-Organ Disease In Clinical Study
6. Chimerix Announces BK Virus Data In Late-Breaking Poster Session At The 24th International Congress Of The Transplantation Society
7. InspireMD Files Amended Registration Statement for Proposed Public Offering of Common Stock
8. Mylan Files Annual Report on Form 10-K for Year Ended Dec. 31, 2012
9. AUL Files Seventh Brief Supporting First Amendment Freedom of Conscience
10. OrbusNeich Files Patent Infringement Actions Against Boston Scientific in Germany and the Netherlands
11. Terumo Medical Corporation Files Patent Infringement Lawsuit Against Vascular Solutions And Lepu Medical Technology Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 28, 2016  ValGenesis, Inc., the market ... (VLMS) today announced that a prominent world ... of chronic kidney failure has selected ValGenesis ... corporate validation process. The global medical device ... to manage their validation processes electronically. Upon ...
(Date:4/27/2016)... April 27, 2016  Hologic, Inc. (Nasdaq: ... results for the fiscal second quarter ended March ... of $0.24 increased 41.2%, and non-GAAP diluted EPS ... increased 5.8% on a reported basis, and 6.3% ... "We posted another good quarter, highlighted by 14.6% ...
(Date:4/27/2016)... 27, 2016   ... in Recurring Consumable Sales  Clinical sales grow ... Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the ... for the first quarter ended March 31, 2016 and ... of its commercial strategy. First Quarter 2016 ...
Breaking Medicine Technology:
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... which is has been collaborating with doctors and hospitals to make transformative changes ... the world’s leading cell therapy minds this week in discussing breakthroughs in cellular ...
(Date:4/28/2016)... ... ... reminds us that May is National Stroke Awareness Month. According to the Centers for ... the United States; someone has one every 40 seconds. Annually, almost 800,000 strokes occur ... A stroke is when blood flow to the brain is blocked or when a ...
(Date:4/28/2016)... Philadelphia, PA (PRWEB) , ... April 28, 2016 ... ... Barbara Browne, M.D. has been named a Top Doc in Physical Medicine and ... in conjunction with Castle Connolly Medical, Ltd. by randomly surveying physicians and medical ...
(Date:4/28/2016)... MO (PRWEB) , ... April 28, 2016 , ... Denise McCormick Baich had written poetry ... 2009 the poetry arrived again much like a tsunami and took on a more spiritual ... to her encouraged her to do more with it than just file it away. Friends ...
(Date:4/28/2016)... ... April 28, 2016 , ... Prescription ... co-operative bankruptcy to receive their prescription medications through America’s fastest-growing pharmacy program. ... medications from over 180 American pharmaceutical companies for $35 per month, per ...
Breaking Medicine News(10 mins):